Prostate Cancer Therapy Choice Does Not Significantly Impact Survival According to Long-Term Clinical Trial Follow-Up
Patients with prostate cancer experienced prostate cancer-specific mortality at a low rate regardless of assigned treatment.
Ide-Cel Leads to Extended PFS, Increased Response Rates in R/R Multiple Myeloma
Patients with relapsed or refractory multiple myeloma experienced improved progression-free survival with idecabtagene vicleucel. Notably, cytokine release syndrome rates were high with this treatment.
Cardioprotective Outcomes Evident With Dexrazoxane in Children Treated With Doxorubicin
Pediatric cancer survivors who received anthracycline-based chemotherapy may derive long-term cardio-protection from dexrazoxane.
Pembrolizumab With or Without Chemotherapy Continues to Show Survival Benefit Over Cetuximab Plus Chemotherapy in Recurrent/Metastatic HNSCC
Patients with head and neck squamous cell carcinoma continued to displayed a survival benefit with pembrolizumab at a 4-year follow-up.
Smoking Cessation Programs Display Reach and Efficacy But Gaps Remain
Research published in the Journal of Clinical Oncology seeks to inform best practices in establishing smoking cessation programs across cancer care centers.
Label Update for Capecitabine Expands and Updates Indications
The FDA has approved updated labeling for capecitabine under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs.
Trastuzumab Deruxtecan Outperforms Trastuzumab Emtansine in DESTINY-Breast03 Follow-Up
Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
Benefit-Risk Profile of Trastuzumab/Pertuzumab With FLOT Regimen Comes Into Question in HER2-positive Gastric Cancer
Trastuzumab and pertuzumab with a chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin, and docetaxel increased response, and high-grade toxicity, in patients with HER2-positive gastric or gastroesophageal junction cancer.
Everolimus Fails to Show DFS Benefit in Aromatase Inhibitor–Resistant Metastatic Breast Cancer
Disease-free survival in patients with metastatic breast cancer did not differ between treatment with everolimus or placebo.
Margetuximab Does Not Surpass Trastuzumab in Terms of Survival in HER2+ Breast Cancer
Margetuximab did not deliver a significant survival benefit in patients with HER2-positive advanced breast cancer compared with trastuzumab.
HRD, BRCA Status May Inform PARP Inhibitor Suitability in Advanced Ovarian Cancer
During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.
Dexamethasone Sparing with Cisplatin-Based Chemotherapy Does Not Significantly Impact QoL
Dexamethasone sparing in cisplatin-based chemotherapy did not impair global health status, although it did worsen nausea and appetite loss.
Updates in Lung Cancer Screening Criteria Increase African American Patient Participation
The expansion of screening criteria is an important step in decreasing lung cancer screening disparities in high-risk populations. Efforts to expand community outreach, overcome logistical barriers, and facilitate screening adherence must still be made, experts say.
Venetoclax/Obinutuzumab Continues to Show Efficacy in Unfit Patients with CLL
An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.
Patritumab Deruxtecan Produces Early Responses in Advanced NSCLC Regardless of Variant Genomic Alterations
Regardless of other identified driver genomic alterations, patients with heavily pretreated, advanced, non–small cell lung cancer achieved encouraging responses with patritumab deruxtecan.
Revolutionizing Patient-Reported Outcomes in Oncology Care
Patient-reported outcome collections continue to yield more effective and personalized treatments for patients with cancer.
GnRH Agonists Demonstrate Utility in Preventing Premature Menopause in Women With Breast Cancer
Current ASCO guidelines recommend that providers discuss the possibility of infertility with their patients as soon as possible before treatment begins.
Newly Approved Pacritinib Continues to Reduce Symptom Burden in Myelofibrosis With Moderate/Severe Thrombocytopenia
Pacritinib helps relieve physical function-related symptoms in adult patients with myelofibrosis and moderate or severe thrombocytopenia.
Niraparib/Bevacizumab Combo Elicits Promising Responses in Advanced Ovarian Cancer, Regardless of Biomarker Status
The PARP inhibitor, niraparib, in conjunction with the VEGF inhibitor, bevacizumab, resulted in encouraging responses from patients with advanced ovarian cancer.
Investigational CAR T-Cell Therapy, Obecabtagene Autoleucel, Is Poised to Fill Unmet Need in Relapsed/Refractory B-ALL
Investigators hope that the novel obecabtagene autoleucel, a second-generation CAR T-cell therapy may fill an unmet need by representing a durable treatment option for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Metastatic Urothelial Cancer Treatments Continue to Gravitate Towards Immunotherapy and Targeted Therapies
A Yale Cancer Center expert offers a quick glance at the metastatic urothelial cancer treatment landscape.
Patients with LBCL Experience Improved Quality of Life Following Axi-Cel Treatment
Axicabtagene ciloleucel improved the quality of life in patients with relapsed/refractory large B-cell lymphoma receiving the agent as a second-line therapy.
Lenvatinib/Pembrolizumab Combo Continues to Show Benefit in Advanced Endometrial Cancer
A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.
COVID-19 Vaccination a Must For Patients With Cancer
Patients with cancer should receive the entire COVID-19 vaccination as soon as possible, according to an expert at the 39th Annual Chemotherapy Foundation Symposium.
Balstilimab Zalifrelimab Combination Yields Promising Results in Recurrent/Metastatic Cervical Cancer
A phase 2 trial presented at the 2021 ESMO Annual Congress showed that Balstilimab plus Zalifrelimab induced superior response rates, duration of responses, and overall survival in patients with recurrent/metastatic cervical cancer.
Copanlisib Plus Rituximab May Be ‘Viable Option’ Across Indolent Non-Hodgkin Lymphoma
More data are needed regarding the duration of response associated with this combination to make it a “mainstream” treatment option for patients, according to an expert from the University of Michigan Rogel Cancer Center.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
2 Clarke Drive Cranbury, NJ 08512